New immunotherapy combo aims to shrink lung tumors before surgery
NCT ID NCT07241819
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests the immunotherapy drug ivonescimab, alone or with chemotherapy, before and after surgery for people with stage II-IIIB non-small cell lung cancer that can be removed. The goal is to see if tailoring treatment based on PD-L1 levels can reduce toxicity while keeping the cancer from coming back. About 66 participants will be split into groups based on their PD-L1 levels and receive different combinations of ivonescimab and chemo before surgery, followed by ivonescimab alone after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ivonescimab (an immunotherapy drug) alone or with platinum-based chemotherapy
- What this could lead to
- If successful, this could offer a more personalized, less toxic treatment approach for resectable lung cancer, potentially improving outcomes while reducing side effects.
- What could go wrong
- This is an early Phase 2 trial with only 66 participants, so results may not apply broadly. The drug may not improve outcomes or could cause serious immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for II-IIIB (T3N2) RESECTABLE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.